预约演示
更新于：2025-05-15
Arbidol Hydrochloride
盐酸阿比多尔
更新于：2025-05-15
概要
基本信息
结构/序列
分子式C22H26BrClN2O3S |
InChIKeyOMZHXQXQJGCSKN-UHFFFAOYSA-N |
CAS号131707-23-8 |
关联
36
项与 盐酸阿比多尔 相关的临床试验NCT06462417
Study on the Efficacy and Safety of Oral Administration of Arbidol in the Treatment of Allergic Rhinitis Patients
CTR20234001
盐酸阿比多尔片在健康受试者中的随机、开放、两制剂、单次给药、部分重复/双交叉的空腹/餐后生物等效性研究
CTR20231395
评估受试制剂盐酸阿比多尔片50mg与参比制剂盐酸阿比多尔片“Арбидол®”50mg作用于健康成年受试者在餐后状态下的单中心、开放、随机、单剂量、三周期、半重复交叉生物等效性研究
100 项与 盐酸阿比多尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸阿比多尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸阿比多尔 相关的专利（医药）
登录后查看更多信息
1,070
项与 盐酸阿比多尔 相关的文献（医药）2025-05-08JOURNAL OF MEDICINAL CHEMISTRY
Strategic Design and Optimization of Umifenovir Analogues: Balancing Antiviral Efficacy and hERG Toxicity against SARS-CoV-2
Article
作者: Joshi, Akshay ; Bokara, Kiran Kumar ; Sardana, Yogesh ; Das, Nirmal ; Das, Dipankar ; Das, Satyajeet ; Patra, Binita ; Singh, Nittu ; Kumar, Sahil ; Martin, Alna Kuriyickal ; Ghosh Dastidar, Uddipta ; Singh Chawla, Ravneet ; Devi, Renuga ; Hoque, Israful ; Talukdar, Arindam ; Ringe, Rajesh P. ; Thakur, Krishan Gopal
Arbidol (ARB, Umifenovir), a broad-spectrum antiviral from Russia, lacks Food and Drug Administration (FDA) approval due to insufficient clinical data and undocumented toxicity concerns. Its indole scaffold, with six unique substitutions, enables optimization for improved efficacy. This study optimized ARB's antiviral potency and safety by modifying the N1, C2, C3, and C4 positions. Antiviral efficacy was evaluated in SARS-CoV-2-infected VERO E6 cells, while optimization was guided by absorption, distribution, metabolism, and excretion (ADME), in vivo pharmacokinetic (PK) and hERG. Early modifications at N1 and C2 produced compounds 10 and 14 (IC50 = 1.5 μM), surpassing ARB (IC50 = 9.0 μM). Further refinements yielded compounds 42 (IC50 = 1.1 μM) and 56 (IC50 = 0.24 μM), resolving hERG toxicity (>30 μM). C3 modifications led to lead compounds 77, 79, and 81 (IC50 = 0.67-0.7 μM), achieving superior potency while eliminating hERG toxicity. Mechanism of entry inhibition and immunofluorescence confirmed compound 77 significantly reduced SARS-CoV-2 within Vero cells, supporting their preclinical potential.
2025-04-01DRUG DEVELOPMENT RESEARCH
Design, Synthesis and Anti‐Influenza Virus Activity of 4‐Tert‐Butyl‐N‐(3‐Oxo‐1‐Thia‐4‐Azaspiro[4.5]Dec‐4‐yl)Benzamide Derivatives That Target Hemagglutinin‐Mediated Fusion
Article
作者: Alikadıoğlu, Zeynep ; Cihan‐Üstündağ, Gökçe ; Çınar, Gözde ; Naesens, Lieve ; Soylu‐Eter, Özge
ABSTRACT:
Hemagglutinin (HA) is a viral glycoprotein that mediates influenza virus entry into the host cell and is considered a relevant viral target. We here report the identification of a class of 4‐tert‐butylphenyl‐substituted spirothiazolidinones as HA‐mediated fusion inhibitors with specific activity against influenza A/H3N2 virus. The novel spirocyclic compounds were achieved by using one‐pot cyclocondensation method and the chemical structures were characterized by IR, 1H NMR, 13C NMR, and elemental analysis. Compound 2c, bearing methyl substitutions at positions 2‐ and 8‐ of the spiro ring displayed an EC50 value against influenza A/H3N2 virus of 1.3 μM and an antiviral selectivity index of 30. The fusion‐inhibiting effect of compound 2c was revealed in the polykaryon assay which is based on cell‐cell fusion when influenza virus H3 HA‐transfected cells are exposed to low pH. Computer‐aided docking was performed to predict the possible binding pocket in the H3 HA trimer. Resistance data and in silico studies indicated that compound 2c has an overlapping binding pocket in the stem region of H3 HA with the known fusion inhibitors TBHQ and arbidol.
2025-03-24Journal of biomolecular structure & dynamics
Inhibition of respiratory syncytial virus by Daclatasvir and its derivatives: synthesis of computational derivatives as a new drug development
Article
作者: Mitra, Debanjan ; Abdalla, Mohnad ; Afreen, Shagufta ; Das Mohapatra, Pradeep K.
The most common cause of respiratory tract illness in newborns and young children is the respiratory syncytial virus (RSV). There is no approved vaccination or specific antiviral medication for RSV infections. Here, an attempt has been made to explore the potential of currently marketed drugs as well as their probable derivatives to improve the possibility of developing stronger medications against RSV. From the 100 synthetic drug compounds library, the best drug molecule was identified through drug-likeness properties, toxicity, molecular docking and molecular dynamics simulations. Molecular Mechanics Generalized Born Surface Area (MM-GBSA) was also a method that was applied in this study. Daclatasvir showed the highest binding energy and appeared as the best drug to inhibit matrix protein and a fusion protein of RSV. Based on Daclatasvir, 40 computational derivatives were made. D28, D34 and D40 showed far better results than the actual drug. Changes in lipophilicity character increase the binding energy of derivatives. Molecular dynamic simulations showed their non-deviated, non-fluctuated and stable complex formation with target proteins. The high number of amino acid contacts throughout the trajectory increases the stability and effectiveness of derivatives. The key to producing a novel medicine to eradicate RSV is provided by derivatives. Daclatasvir will be employed as a potential RSV inhibitor up until that point.
65
项与 盐酸阿比多尔 相关的新闻（医药）2025-05-14
生物类似药疫苗临床研究
2025-04-21
·米内网
临床1期申请上市临床申请
2025-04-13
·信狐药迅
疫苗信使RNA申请上市上市批准临床申请
100 项与 盐酸阿比多尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 甲型流感病毒感染 | 俄罗斯 | - | 1993-01-01 |
| 乙型流感病毒感染 | 俄罗斯 | - | 1993-01-01 |
| 呼吸道感染 | 俄罗斯 | - | 1993-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床3期 | 印度 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 99 | standard-of-care +arbidol | 築醖網夢鹹鏇夢鑰醖網(鹽網窪鏇築網繭構蓋齋) = 齋膚淵齋憲窪鏇憲選簾 夢鑰選襯蓋鏇憲遞願範 (壓獵憲遞衊獵壓襯網顧 ) 更多 | 积极 | 2022-07-14 | ||
standard-of-care | 築醖網夢鹹鏇夢鑰醖網(鹽網窪鏇築網繭構蓋齋) = 繭鹹構餘觸襯鬱窪築醖 夢鑰選襯蓋鏇憲遞願範 (壓獵憲遞衊獵壓襯網顧 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用